JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Larimar Therapeutics (NASDAQ:LRMR) and maintained a $25 price target.
May 31, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Larimar Therapeutics and maintained a $25 price target, indicating strong confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $25 by JMP Securities suggests strong confidence in Larimar Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100